Airway smooth muscle cells: contributing to and regulating airway mucosal inflammation?

K.F. Chung

ABSTRACT: In addition to its contractile properties, airway smooth muscle may contribute to the pathogenesis of asthma by increased proliferation, and by the expression and secretion of pro-inflammatory cytokines and mediators.

Studies of airway smooth muscle cells in culture have shown that many mitogenic mediators can induce proliferation, and that these may therefore, contribute to the increase in airway smooth muscle mass observed in asthma. Other mechanisms for airway smooth muscle proliferation include the interaction with inflammatory cells such as T-cells and eosinophils.

Airway smooth muscle cells may also be a source of inflammatory mediators and cytokines, in particular chemokines, thus implicating airway smooth muscle cells as contributors to the inflammatory mechanisms of asthma. The pro-activating signals for converting airway muscle smooth cells into a proliferative and secretory cell in asthma are unknown, but may include viruses and immunoglobulin E. Airway smooth muscle contractility may also be altered in response to inflammation.

Airway smooth muscle cells may play an important interactive role with inflammatory and other structural cells, contributing to inflammation, injury and repair of the airways. Such a recognition makes it imperative to consider the airway smooth muscle as a target of therapeutic drugs for suppressing not only the contractile but also the proliferative and secretory effects of asthma.

In inflammatory diseases of the airways, the airway smooth muscle has long been regarded as mainly passive, responding only to the release of bronchoconstrictor mediators from other neighbouring cells by contraction, leading to narrowing of the airways and airways obstruction. The mechanical, structural and biochemical properties of the contractile proteins of the airway smooth muscle have been relatively well studied [1], and an increase in the contractile properties of the airway smooth muscle in asthma is considered to be a fundamental abnormality of the disease [2]. Contractile mediators such as histamine and leukotrienes are important in inducing airway smooth muscle shortening and contraction [3]. The maximum capacity and velocity of shortening in human bronchial smooth muscle from patients with asthma are greater than those from healthy subjects [1]. An increase in force generation of the airway smooth muscle mass may result from increased proliferation; in addition, other concomitant factors may also result from an increased airway smooth muscle mass such as increased thickening of the airway wall, which may contribute to overall contractile hyperresponsiveness [4–6].

In vitro studies indicate that the airways smooth muscle cell can maintain a proliferative phenotype in response to contractile agents, inflammatory mediators and growth factors [7]. Morphometric studies of airway smooth muscle in asthma have demonstrated that there is an increase in airway smooth muscle mass which is accounted for by hyperplasia and also by hypertrophy [4, 5]. Such an increase in airway smooth muscle mass could contribute to the exaggerated airway narrowing observed in asthma [6, 8] and may result from the action of growth factors released during the chronic inflammatory process. It has yet to be demonstrated that airway smooth muscle in asthma has a proliferative phenotype. However, in some animal models, increased proliferation of the airway smooth muscle following repeated allergen exposures after sensitization occurs [9–11]. In addition to the direct interaction of growth factors on the airway smooth muscle, the possibility that inflammatory cells, such as T-cells, could
interact directly with the airway smooth muscle to induce proliferation has been raised [12]. Removal of serum factors that induce proliferation of airway smooth muscle in vitro following confluence results in a population of elongated cells with an ability to shorten considerably [13], together with an increase in smooth muscle α-actin and myosin heavy chain [14]. The question is whether there is such a heterogeneity of airway smooth muscle cells in vivo particularly in thickened airway smooth muscle of patients with asthma, and whether these cells contribute to the increased responsiveness of the airways.

Studies derived mainly from isolated airway smooth muscle cells in culture indicate that the airway smooth muscle can also exhibit a synthetic potential with the elaboration of inflammatory mediators including cytokines, and also importantly, the muscle can respond to its inflammatory milieu by expressing and releasing proteins that render the muscle cell a potentially active participant of the inflammatory response. Therefore, the airway smooth muscle could exhibit various states: a synthetic phase, a proliferative phase as well as a contractile phase (fig. 1). These states may coexist in the same cell and may be examined separately in airway smooth muscle cells in vitro.

**Airway smooth muscle cells in culture**

Cultured airway smooth muscle cells [15, 16] have provided a convenient model system for studying the regulation of a wide range of airway responses at the cellular level. The most common method used is to dissociate cells from a minced preparation of airway smooth muscle, usually from trachealis or sometimes from the major bronchi, using collagenase and elastase to degrade collagen and elastin from the associated matrix. Other methods include the use of small explants of dissected smooth muscle to generate primary cultures. After growing to confluence usually in the presence of foetal calf serum (FCS), the cells can be removed from their growth support and reseeded at subconfluent cell density and allowed to proliferate again. Airway smooth muscle cells in culture possess specific features recognized to be characteristic of cultured smooth muscle cells in general. Nonmuscle contaminants such as epithelial or connective tissue cells (fibroblasts) can be distinguished from airway smooth muscle cells by immunostaining for smooth muscle α-actin and smooth muscle specific myosin heavy chain. In airway smooth muscle cells, the pattern of staining is that of filamentous contractile proteins arranged in parallel to the long axis of the cells. Usually little change in cell number occurs over the first 3–4 days after plating, with few cell-to-cell contacts existing, with spindle-shaped morphology that is characteristic of cultured vascular smooth muscle cells. Cell numbers begin to increase after 4 days, until confluence is reached by 7–10 days after initial seeding. At confluence, the cells exhibit in several layers and cultures exhibit a hill and valley pattern typical of airway smooth muscle cells in culture.

The contractile phenotype of airway smooth muscle cells under culture is well recognized in enzyme dissociated cells seeded in primary culture within 24–48 h, with intense immunostaining for muscle specific contractile proteins and with visible contraction to constrictor agonists. Serum deprivation allows the acquisition of a subpopulation of myocytes with a morphological and functional contractile phenotype [14]. In the presence of proliferating stimuli, such as FCS, contractile airway smooth muscle changes into a "synthetic" phenotype, characterized by: increased mitogenic activity; expression of intracellular organelles associated with synthesis; and a decrease in immunostaining for smooth muscle specific contractile proteins. In proliferating tracheal smooth muscle cells, the levels of smooth muscle myosin heavy chain are markedly reduced with a reduction in messenger ribonucleic acid (mRNA) for this protein and α-actin, with some reduction in myosin light chains [17]. The synthetic cells produce extracellular matrix components and also autocrine growth-promoting factors, and these could in turn influence the contractile or synthetic phenotype, as described primarily in vascular smooth muscle cells [18–20]. In vascular smooth muscle cells, phenotypically distinct cells with enhanced growth potential have been shown to exist within the normal arterial media [21].

**Synthesis of pro-inflammatory proteins**

Studies of cultures of airway smooth muscle cells have now demonstrated that these cells can release several inflammatory mediators under various conditions of stimulation. This raises the likelihood that airway smooth muscle cells may contribute to chronic inflammatory processes in the airway. Dissociated airway smooth muscle cells in culture usually grown to a stage of confluence, then serum-deprived, have been studied. A list of these inflammatory mediators is shown in table 1.

**Products of lipid metabolism**

Airway smooth muscle cells are an important source of cyclooxygenase products with predominantly prostaglandin (PG)E₂ and prostacyclin, with relatively little formation of thromboxane following stimulation with a mixture of interleukin (IL)-1β, tumour necrosis factor (TNF)α and interferon (IFN)γ ("cytomix"), through the induction of the cyclooxygenase enzyme-2 (COX-2) [22]. Bradykinin also causes release of PGE₂ from human airway smooth muscle cells, also mediated through the induction of COX-2 [23]. Cytokines also induce the secretory form of phospholipase A₂ from airway smooth muscle cells [24]. Cultured human airway smooth muscle cells express mRNA...
Chemokines such as regulated upon activation, normal T-cell expressed and secreted (RANTES), eotaxin, and monocyte chemotactrant protein (MCP)-3 are chemotactrant cytokines which are expressed in asthmatic airways, and may be important in causing chemotaxis and activation of inflammatory cells such as eosinophils, T-cells and macrophages [26–29]. RANTES is an eosinophil and T-cell chemotactrant. Stimulation of airway smooth muscle cells with TNFα caused expression of RANTES mRNA and protein release, an effect augmented by IFNγ [30]. The RANTES fraction from the supernatants caused eosinophil chemotaxis in vitro. The T-helper (Th)-2 T-cell derived cytokines, IL-4, IL-10 and IL-13, as well as dexamethasone inhibited RANTES mRNA and protein expression. The more selective eosinophil chemotactrant, eotaxin, is also expressed in human airway smooth muscle cells stimulated by IL-1β or TNFα [31, 32]. Both IL-1β and TNFα-induced release of eotaxin was not inhibited by corticosteroids, in contrast to the release of RANTES [31]. The eosinophil chemotactrant activity of stimulated airway smooth muscle supernatants appears to be predominantly accounted for by RANTES and eotaxin [30, 32]. Other C-C chemokines that are released include MCP-1, -2 and -3 from airway smooth muscle cells stimulated with a mixture of IL-1β, TNFα and IFNγ, effects inhibited by dexamethasone but not by the Th2 cytokines, IL-4, IL-10 and IL-13 [33, 34]. There is no evidence for the release of macrophage inflammatory protein-1α [30]. Following stimulation with IL-1β and bradykinin, airway smooth muscle cells can express and release IL-8, a potent neutrophil chemotactrant [35, 36].

### Pro-inflammatory cytokines

Airway smooth muscle cells generate granulocyte-macrophage colony-stimulating factor (GM-CSF) under stimulation with the cytokine mixture of IL-1β, TNFα and IFNγ [37]. Supernatants of airway smooth muscle cells stimulated by IL-1β caused increased survival of eosinophils [38], an effect blocked by an anti-GM-CSF antibody, thereby implying GM-CSF as the cytokine responsible for eosinophil survival. Human airway smooth muscle cells are also potent producers of IL-11 when stimulated with IL-1 and transforming growth factor (TGF)β1 in combination, and when incubated with respiratory syncytial virus and parainfluenza virus type 3 [39]. Other IL-6-type cytokines such as IL-6 and leukaemia inhibitory factor are also released on stimulation with IL-1 and TGFβ1 [39]. IL-6 is also produced by cross-linking CD40 [40]. Sensitization of airway smooth muscle cells with asthmatic atopic serum leads to the expression and release of IL-5 and IFNγ, together with the mRNA expression for their receptors. There was no increase in IL-4 expression [41]. There was also enhanced expression of the Th1 cytokines IL-2, IL-12 and IFNγ, and of their receptors. These results indicate that both Th1 and Th2 cytokines can be produced by airway smooth muscle cells.

### Mediators of airway smooth muscle proliferation

Many studies have characterized the stimulation of airway smooth muscle growth *in vitro* in response to mitogenic agents such as polypeptide growth factors (e.g. platelet-derived growth factor (PDGF) [42, 43], epidermal growth factor (EGF) [44], insulin-like growth factor (IGF) [45], inflammatory mediators (e.g. endothelin (ET)-1, histamine) and cytokines (e.g. IL-1β, TNFα and IL-6). IL-1β, TNFα and IL-6 induce proliferation of airway smooth muscle, but usually in the presence of a cyclooxygenase inhibitor which prevents the induced secretion of protective PGE2 [46, 47]. The effect of IL-1β appears to be mediated via PDGF formation [48]. Histamine stimulates proliferation *via* activation of c-fos [49], and ET-1 induced proliferation *via* the stimulation of extracellular-regulated kinase microtubule associated protein kinase pathway [50]. More importantly, ET-1 and LTD4 amplify the proliferative effect of growth factors such as EGF [51, 52]. In *in vivo* studies in a Brown-Norway rat model show that sulphidopeptide leukotrienes and ET-1 are both involved in allergen-induced increases in airway smooth muscle proliferation [9, 53, 54]. Finally, activated T-cells can adhere to airway smooth muscle and induce its proliferation [12].

In addition to responding to proliferative factors, airway smooth muscle cells can also produce some of the factors that can modulate its proliferation. Nitric oxide is produced from the airways during inflammation. Type I nitric oxide synthase (NOS) is constitutively expressed by cultured human airway epithelial cells, but not Type II NOS (inducible NOS) even after exposure to IL-1β, TNFα and PDGF-βB.
IFNγ [55]. Nitric oxide can inhibit deoxyribonucleic acid (DNA) synthesis and the proliferation of airway smooth muscle. Reactive oxygen species generated by an oxidoreductase of reduced nicotinamide adenine dinucleotide are required for serum or PDGF-induced growth of airway smooth muscle cells [56]. Furthermore, superoxide dismutase mimetics are capable of inhibiting serum-induced proliferation of airway smooth muscle cells [55]. Insulin-like growth factor (IGF) 2 is produced by cultured rabbit airway smooth muscle cells at concentrations that can stimulate proliferation [45]. IGF binding protein (IGFBP)-2 is also produced. An expression of the BB isoform of PDGF (PDGF-BB) mRNA and protein was observed in guinea-pig airway smooth muscle cells on exposure to IL-1β, associated with proliferation, which was ablated by antibodies to PDGF-BB [48]. This study by Drs et al. [48] suggests that PDGF-BB may be released from airway smooth muscle cells. Other growth factors such as basic fibroblast growth factor may increase the expression of PDGF α-receptor and the binding of PDGF-AA to airway smooth muscle cells. An induction of matrix metalloprotease (MMP)-1 by LTD4 in airway smooth muscle has been reported [57]. Since MMP-1 acts as a protease for IGFBP-2, causing its degradation, the effects of IGF can be enhanced, thus explaining the synergy between LTD4 and IGF on airway smooth muscle proliferation. Elevated levels of MMP-1 have been demonstrated in airway smooth muscle cells in patients with asthma [58]. PGE2 produced by airway smooth muscle cells is anti-proliferative [59].

Human bronchial smooth muscle cells are also capable of producing stem cell factor which is a ligand of the c-kit proto-oncogene and which is an important growth factor for human mast cells [60]. Both soluble and membrane-bound stem cell factor mRNA are expressed. This indicates that airway smooth muscle cells could increase human mast cells within their vicinity as has been shown in asthmatic airways [61], and that direct release of mediators from mast cells could primarily affect airway smooth muscle.

Interactions of airway smooth muscle cells with pro-inflammatory and immune cells

Interaction of airway smooth muscle cells with inflammatory cells may occur following expression of cell adhesion molecules on the surface of airway smooth muscle cells which may lead to direct contact of inflammatory cells on airway smooth muscle. There is increased expression of α1 and α2 integrins, very late activation antigen (VLA)-4 and lymphocyte function associated receptor (LFA)-1, in bronchial biopsies of patients with asthma [62–64]. Airway smooth muscle cells express intercellular adhesion molecule (ICAM)-1 and vascular cell adhesion molecule (VCAM)-1 at barely detectable levels, but upregulate these adhesion molecules after treatment with TNFα for 24 h. Lipopolysaccharide, IL-1 and IFN also increased ICAM-1 expression, while VCAM-1 expression was increased by TNF and IL-1 [12]. Activation of T-cells is required for adhesion to airway smooth muscle cells. This binding of T-cells to airway smooth muscle is partially prevented when activated T-cells are pretreated with monoclonal antibodies against LFA-1 or when airway smooth muscle cells were pretreated with antibodies to ICAM-1. A combination of antibodies against LFA-1 and VLA-4, or ICAM-1 and VCAM-1 inhibited binding to a greater extent than anti-LFA-1 or anti-ICAM-1 alone. A combination of LFA-1, VLA-4 and CD44 antibodies acted synergistically to reduce the binding of activated T-cells, but CD44 antibodies alone had no effects. Activation of cyclic adenosine monophosphate (cAMP)-dependent pathways inhibits TNFα-induced ICAM-1 and VCAM-1 expression and T-cell adhesion [65]. Anti-CD3-stimulated peripheral blood T-cells also adhere to airway smooth muscle cells and upregulated ICAM-1 expression and induce the expression of major histocompatibility complex (MHC) Class II [66]. The induction of ICAM-1 was partly dependent on IFNγ. Bronchoalveolar lavage T-cells from atopic subjects following allergen challenge adhered to airway smooth muscle, with upregulation of ICAM-1 and human leukocyte antigen (HLA)-DR. Stimulation of airway smooth muscle cells by IFNγ leads to the expression of MHC Class II antigens, but airway smooth muscle cells were not capable of presenting alloantigen to CD4+ T-cells. CD40, a member of the TNF receptor family, is expressed on cultured human airway smooth muscle cells and is increased by TNFα or IFNγ [40]. Cross-linking CD40 on airway smooth muscle cells resulted in enhanced IL-6 secretion and an increase in intracellular calcium concentrations. CD40-mediated signaling events include protein tyrosine phosphorylation and activation of the transcription factor, nuclear factor (NF)-κB [40].

Effects of inflammatory factors on airway smooth muscle contractility

Interactions of airway smooth muscle with inflammatory factors may lead directly to changes in airway smooth muscle contractility. Intratracheal administration of IL-1β to rats induced an attenuation of β-adrenergic receptor-induced airway relaxation through mechanisms involving a reduction in β-adrenoceptors and an increase in the inhibitory G protein, Gi protein, Giα subunit, coupled to a reduction in adenyl cyclase activity [67]. Similar observations were made with in vitro human airway smooth muscle cells incubated with IL-1β with a decreased response in muscle stiffness to isoprenaline mediated by uncoupling of β-receptors from stimulatory Giα subunit-induced activation of adenyl cyclase, perhaps through the release of PGE2 [68, 69]. TNF-α can also induce a reduction in isoprenaline-stimulated adenyl cyclase activity [70], together with increased expression of Grα1.2 and Giα but not of Giα proteins [71]. Passive sensitization of isolated rabbit airways with serum derived from atopic asthmatic subjects with high serum immunoglobulin (Ig)E levels demonstrated increased maximal isometric contraction and sensitivity to acetylcholine. There was also attenuation of relaxation of acetylcholine-induced contraction to isoprenaline [72, 73]. Gi protein expression was increased in sensitized airway smooth muscle, due to enhanced Giα subunit, and increased muscarinic M2 receptor [71], effects attributed to an induced release of IL-1β [74, 75]. Autocrine pro-inflammatory signalling and altered receptor/G protein-coupled second messenger accumulation and action may contribute to increase airway smooth muscle contractility in asthma and decrease responsiveness to β-adrenergic agonists.
Atopic asthmatic serum-sensitized human tracheal smooth muscle cells exhibit mRNA and cell surface expression of the low affinity receptor for IgE, FcεRII, an effect that was inhibited by pretreatment with anti-CD23 monoclonal antibody [75]. FcεRII is reported to be increased in asthmatic airway smooth muscle [76]. The anti-CD23 antibody blocked the increase in maximal isometric contractility to acetylcholine induced by serum-treated tracheal smooth muscle strips. Passive sensitization of human bronchial smooth muscle also increases both shortening velocity and capacity, and myogenic contractions to quick stretch, an effect that was related to IgE concentrations in sensitizing sera [77, 78]. Receptors for various cytokines have been found in airway smooth muscle cells passively-sensitized with atopic serum, for receptors for IL-5, GM-CSF, IL-2, IL-12 and IFNγ. Thus, IL-5 and GM-CSF can increase acetylcholine contractility and reduce relaxant responses to isoprenaline [41], while IL-2 and IFNγ prevented the increase in contractility to acetylcholine after passive sensitization. Airway smooth muscle from sensitized dogs demonstrates an increased velocity of shortening contributing to increased total shortening of the sensitized muscle but not isometric force, associated with increased gene and protein expression of myosin light chain kinase [79, 80].

Viral infections of the upper respiratory tract are recognized as important triggers of asthma exacerbations. Incubation of rhinovirus with airway smooth muscle cells increases airway smooth muscle responsiveness to acetylcholine and attenuated relaxation to isoprenaline, an effect related to diminished isoprenaline-induced cAMP accumulation and upregulated expression of Gβγ3, effects that were triggered by binding of the rhinovirus to its ICAM-1 receptor in airway smooth muscle [81].

**Significance of in vitro observations on airway smooth muscle with regard to asthma**

Directly relating data obtained using cultured airway smooth muscle cells to *in vivo* circumstances is likely to be confounded by the tendency for phenotypic modulation of airway smooth muscle cells under normal cell culture conditions. In addition, it is still unclear exactly how a proliferative phase links with the synthetic phase which represents an airway smooth muscle cell in a synthetic type, rather than a contractile phenotype and inflammation change phenotype to a more proliferative versus antiproliferative cytokines and mediators remains to be determined. For example, production of GM-CSF could induce the muscle to increase its own contractility. Regarding the potential phenotypic changes, it is pertinent to ask whether airway smooth muscle cells during inflammation change phenotype to a more proliferative and synthetic type, rather than a contractile phenotype and whether some of the airway smooth muscle cells may change into a myofibroblast phenotype that is secretory. The migratory potential of myofibroblasts has been demonstrated following allergen challenge [83], but where they originate, within a matter of hours following allergen challenge, is unknown. Myofibroblasts have contractile properties and express actin filaments but not myosin, and the lineage relationship among fibroblasts, myofibroblasts and smooth muscle cells is not clear. Airway smooth muscle cells may be a source of myofibroblasts, possibly representing an airway smooth muscle cell in a synthetic phase. Proliferation of the smooth muscle cells may depend on its own elaboration of proliferative versus antiproliferative cytokines and mediators and whether the proliferative state is also associated with a secretory phase for certain cytokines/mediators remains to be determined.
Conclusion

These new findings about the airway smooth muscle cell should change the perception of airway smooth muscle: far from being solely contractile, airway smooth muscle cells being influenced by inflammatory factors may participate in and regulate airway mucosal inflammatory processes by changing the phenotype and by secreting pro-inflammatory cytokines, mediators and enzymes. These could lead to interactions between the airway smooth muscle cells and inflammatory cells such as T-cells and eosinophils, as well as their surrounding matrix. New approaches to its study particularly in vivo are essential to determine whether these changes can occur in diseases such as asthma and chronic bronchitis. A complex relationship between airway smooth muscle contractility, its proliferative state, and its hypersecretory mode probably exists in disease and deserves further analysis.

This is of relevance to asthma therapy since the action of a β2-adrenergic agonist may be less effective on airway smooth muscle that is in a hypersecretory or proliferative mode. The effects of a β2-adrenoceptor agonist on hypercontractile airway smooth muscle may also be diminished, and could also be another reason for reduced effectiveness of β2-adrenoceptor agonists such as occurs during exacerbations of asthma. Because airway smooth muscle cells can produce inflammatory cytokines, they could be considered as a target for anti-inflammatory therapy in asthma, such as corticosteroids. Corticosteroids can inhibit the induced release of RANTES, IL-8, GM-CSF and MCP-1 from airway smooth muscle cells in vitro, although they are not effective in inhibiting cytokine release. In addition, they inhibit thrombin-induced airway smooth muscle proliferation through an inhibition of cyclin protein expression [84, 85].

Targeting the airway smooth muscle cell in terms of inhibition of its proliferative and secretory potential may represent a likely successful path for novel treatments that could prevent its excessive contractility and increased thickening in asthma.

References


55. Patel H, Belvisi MG, Donnelly LE, Yacoub M, Chung KF, Mitchell JA. Constitutive expression of type 1 NOS


